Yifan Pharmaceutical Statistics

Total Valuation

Yifan Pharmaceutical has a market cap or net worth of CNY 14.61 billion. The enterprise value is 15.89 billion.

Market Cap	14.61B
Enterprise Value	15.89B

Important Dates

The next estimated earnings date is Monday, October 28, 2024.

Earnings Date	Oct 28, 2024
Ex-Dividend Date	Sep 25, 2024

Share Statistics

Yifan Pharmaceutical has 1.22 billion shares outstanding. The number of shares has decreased by -2.94% in one year.

Shares Outstanding	1.22B
Shares Change (YoY)	-2.94%
Shares Change (QoQ)	-1.75%
Owned by Insiders (%)	41.84%
Owned by Institutions (%)	8.28%
Float	707.46M

Valuation Ratios

PE Ratio	n/a
Forward PE	26.69
PS Ratio	3.09
PB Ratio	1.72
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 34.87, with an EV/FCF ratio of -95.86.

EV / Earnings	-39.08
EV / Sales	3.34
EV / EBITDA	34.87
EV / EBIT	107.50
EV / FCF	-95.86

Financial Position

The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.26.

Current Ratio	1.38
Quick Ratio	0.89
Debt / Equity	0.26
Debt / EBITDA	4.86
Debt / FCF	-13.36
Interest Coverage	2.17

Financial Efficiency

Return on equity (ROE) is -8.55% and return on invested capital (ROIC) is 0.84%.

Return on Equity (ROE)	-8.55%
Return on Assets (ROA)	0.75%
Return on Capital (ROIC)	0.84%
Revenue Per Employee	1.12M
Profits Per Employee	-96,101
Employee Count	4,230
Asset Turnover	0.38
Inventory Turnover	2.47

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.22% in the last 52 weeks. The beta is 0.96, so Yifan Pharmaceutical's price volatility has been similar to the market average.

Beta (5Y)	0.96
52-Week Price Change	+0.22%
50-Day Moving Average	11.26
200-Day Moving Average	12.39
Relative Strength Index (RSI)	57.49
Average Volume (20 Days)	11,219,786

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Yifan Pharmaceutical had revenue of CNY 4.76 billion and -406.51 million in losses. Loss per share was -0.33.

Revenue	4.76B
Gross Profit	2.21B
Operating Income	147.76M
Pretax Income	-679.08M
Net Income	-406.51M
EBITDA	439.69M
EBIT	147.76M
Loss Per Share	-0.33

Full Income Statement

Balance Sheet

The company has 867.60 million in cash and 2.21 billion in debt, giving a net cash position of -1.35 billion or -1.11 per share.

Cash & Cash Equivalents	867.60M
Total Debt	2.21B
Net Cash	-1.35B
Net Cash Per Share	-1.11
Equity (Book Value)	8.44B
Book Value Per Share	7.00
Working Capital	1.06B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 338.92 million and capital expenditures -504.63 million, giving a free cash flow of -165.71 million.

Operating Cash Flow	338.92M
Capital Expenditures	-504.63M
Free Cash Flow	-165.71M
FCF Per Share	-0.14

Full Cash Flow Statement

Margins

Gross margin is 46.47%, with operating and profit margins of 3.11% and -8.55%.

Gross Margin	46.47%
Operating Margin	3.11%
Pretax Margin	-14.28%
Profit Margin	-8.55%
EBITDA Margin	9.24%
EBIT Margin	3.11%
FCF Margin	-3.48%

Dividends & Yields

This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 1.59%.

Dividend Per Share	0.20
Dividend Yield	1.59%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.94%
Shareholder Yield	4.53%
Earnings Yield	-2.77%
FCF Yield	-1.13%

Dividend Details

Stock Splits

The last stock split was on May 16, 2016. It was a forward split with a ratio of 2.5.

Last Split Date	May 16, 2016
Split Type	Forward
Split Ratio	2.5

Scores

Yifan Pharmaceutical has an Altman Z-Score of 3.7.

Altman Z-Score	3.7
Piotroski F-Score	n/a